ESR1 and breast carcinoma: Zhang et al. [180] found that a novel anti-estrogen therapy-related ESR1/miR-130b-3p/HOTAIR network significantly correlated with poor survival in breast cancer patients with following systemic treatment (anti-estrogen therapy).